The human homologue of the Drosophila segment polarity gene patched is mutated in the cancer predisposition syndrome naevoid basal cell carcinoma syndrome (NBCCS), as well as in several types of tumour associated with the disorder. It was recently reported that a single recurrent mutation in the SONIC HEDGEHOG gene, which encodes the PATCHED ligand, was found in one of 43 basal cell carcinomas (BCCs), one of 14 medulloblastomas and one of six breast carcinomas analysed (Oro et al., 1997) . We have searched extensively for this same mutation in a large collection of BCCs, medulloblastomas and carcinomas of the breast, ovary and colorectum and have failed to detect the mutation in any sample analysed.
Keywords: Hedgehog; patched; mutation The hedgehog/patched signalling pathway has been implicated in tumorigenesis by the ®nding that the human PATCHED (PTCH) gene is mutated in the cancer predisposition syndrome nevoid basal cell carcinoma syndrome (NBCCS), as well as in sporadic basal cell carcinomas (BCCs) and medulloblastomas (Hahn et al., 1996a; Johnson et al., 1996; Pietsch et al., 1997) . NBCCS is an autosomal dominant disorder which results in developmental anomalies in addition to cancer predisposition. The developmental phenotype is thought to be due to haploinsuciency in the heterozygous state, with tumours developing when the second PTCH allele is mutated in a given cell. In this respect PTCH acts as a tumour suppressor gene.
In Drosophila the hedgehog/patched signalling pathway is important in establishing the anterior-posterior axis of the developing embryo as well as in patterning the wings and limbs. The pathway is conserved in vertebrates where it is important in the developing neural tube, axial skeleton and limbs (Hahn et al., 1996b; Goodrich et al., 1996) . The ptc gene encodes a twelve-pass transmembrane protein which has been shown to function as the receptor for the Hedgehog (Hh) signal in a heteromeric receptor complex which also involves an additional membrane bound protein smoothened (Smo) (Marigo et al., 1996; Stone et al., 1996) . The current model predicts that while Ptc acts as the ligand binding component of this receptor complex, Smo is responsible for transducing the Hh signal. In the absence of bound Hh, Ptc inhibits Smo signalling and thus transcriptionally represses downstream genes normally activated by Hh signalling. In this respect the action of Ptc is functionally opposed by Hh such that the transcriptional activity of downstream target genes is determined by an interplay between Hh signalling and Ptc activity. Known targets of this pathway include members of the Wnt and TGFb families, molecules which have themselves been implicated in tumorigenesis.
Recently it has been shown that transgenic mice overexpressing Sonic hedgehog (Shh), one of the mammalian Hh homologues, under the control of the keratin 14 (K14) promoter develop BCC-like skin lesions within a few days of skin development (Oro et al., 1997) . These same investigators reported that human SHH is mutated in three independent tumour types. They found the same H133Y missense mutation in one of 43 BCCs, one of 14 medulloblastomas, and one of six breast carcinomas analysed. Given the opposing actions of hedgehog and patched these data suggest that in some cases SHH may act as an oncogene, and the mutation reported leads to its activation. In view of the reported frequency of this recurrent mutation we analysed an extensive collection of common tumour types for the same mutation.
The SHH mutation reported by Oro et al. results in loss of a recognition site for the restriction enzyme MscI making it possible to screen for this mutation by direct digestion of PCR products. The exon 2 fragment ampli®ed by the reported primers contains two additional sites for MscI, providing a control for successful digestion (Figure 1) . We have analysed 36 BCCs, 55 medulloblastoma biopsies from 52 dierent patients, eight medulloblastoma cell lines, 44 breast carcinomas, eight breast carcinoma cell lines, 48 ovarian tumours and 85 colorectal tumours (Table 1) . In all cases the digestion pattern indicated that no mutation was present. When analysed statistically, the frequency of this mutation is signi®cantly lower in our panel of breast cancer cell lines and primary tumours (0/56) than the frequency (1/6) reported by Oro et al.
(two-sided P value = 0.030; Fisher's Exact Test), and the dierence in the frequency in medulloblastomass (1/14 reported previously compared to 0/60 in our study) approaches signi®cance (two-sided P value = 0.066; Fisher's Exact Test).
Given the involvement of the PTCH gene in human tumorigenesis it is not unreasonable to propose that other members of this important developmental pathway may play a similar role. This is supported by the ®nding that MAD-related genes which are involved in signalling by receptors for the TGFb superfamily, putative downstream targets of the HH pathway, are mutated in pancreatic and colorectal tumours (Hahn et al., 1996c; Eppert et al., 1996) . Given the close association of HH, PTCH and SMO it is likely that any oncogenic mutation in HH or SMO may occur in the same tumour types which are seen in increased incidence NBCCS. BCCs are the most prevalent tumours seen in NBCCS individuals, and of the 36 analysed four have already been shown to have a mutation in PTCH by scanning of 20/23 coding exons by single strand conformational polymorphism (SSCP) analysis (C Wicking, unpublished data). Medulloblastomas are also seen at increased frequency in NBCCS, and we have recently shown that mutations in PTCH are seen exclusively in the rare desmoplastic histopathological subtype of medulloblastoma, which is the dominant subtype seen in NBCCS (Pietsch et al., 1997) . Of the samples which we analysed for the SHH mutation one of the cell lines and eight of the 55 biopsies were of the desmoplastic subtype, and three of these biopsies had previously been shown to have a mutation in PTCH (Pietsch et al., 1997) . Interestingly, No SONIC HEDGEHOG mutation in a range of tumours C Wicking et al the reported mutation was found most frequently in breast carcinoma (1/6), a tumour which has not previously been associated with NBCCS. The same investigators have also reported mutations in PTCH in 2/7 breast carcinomas (Xie et al., 1997) , implying that the hedgehog/patched pathway is a major determinant in the development of breast cancer. We found no evidence of the SHH mutation in the 48 primary breast carcinomas and eight cell lines analysed, but have not analysed these tumours for mutations in PTCH.
Failure to identify the previously reported SHH mutation in our extensive collection of tumours suggests that this mutation is extremely rare, but these data do not rule out the possibility that SHH and other members of this pathway are involved in some way in the molecular pathology of these tumours.
